Clinical Trial Update: Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update reports results from CaboNivoIpi (cabozantinib, nivolumab, ipilimumab) in advanced differentiated thyroid cancer, including safety and effi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Follicular Thyroid Carcinoma
• Hurthle Cell Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Poorly Differentiated Thyroid Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-31